Project Grant R01CA299613
Award Date 9/12/25
Completion Date 8/31/30
Dollars Obligated $529K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
- The National Cancer Institute awarded a $244,228 Project Grant to the University of Texas MD Anderson Cancer Center to develop a proteomics-driven approach to accurately map patient tumor samples to preclinical models in lung cancer research under the Cancer Detection and Diagnosis Research federal grant program (CFDA 93.394). The goal is to expand proteomic profiling of lung cancer patient-derived xenograft (PDX) models using reverse-phase protein arrays (RPPAs) to build a comprehensive...
- The National Cancer Institute (NCI) awarded a $654,197 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The General Hospital Corporation (Massachusetts General Hospital) to develop and characterize patient-derived xenograft (PDX) tumor models that represent the major molecular subtypes of pancreatic ductal adenocarcinoma (PDAC). The grant aims to: 1) define the molecular subtypes of PDAC that respond to standard-of-care chemotherapies, 2) elucidate the contribution of...
- This federal Project Grant award of $169,884, funded by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) program, supports research to investigate the molecular mechanisms regulating the POU2F3 oncoprotein and its potential as a therapeutic target for the POU2F3-positive subtype of small cell lung cancer (SCLC-P). The award, with a period of performance from Jul 1, 2025 to Jun 30, 2027, will be carried out by the Beth Israel Deaconess Medical Center, Inc. (Bidmc) in...
- The National Cancer Institute (NCI) awarded a $1,396,152 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of Chicago. The grant, with a project period from December 5, 2024 to November 30, 2029, aims to examine the role of the BNIP3 gene and mitophagy (the selective degradation of mitochondria) in muscle atrophy during cancer cachexia, which is prevalent in pancreatic ductal adenocarcinoma (PDAC). The research will utilize genetically engineered mouse...
- The federal Project Grant award of $411,404.00 from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) supports research at Baylor College of Medicine to identify genes with a significant deficit of loss-of-function mutations in lung tumors. The research aims to determine cancer-related genes that are essential for tumor cell survival and proliferation, but are "prohibited" from having loss-of-function mutations. The findings from this study are...
- The National Cancer Institute (NCI) awarded a $701,538 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Icahn School of Medicine at Mount Sinai (ISMMS) to conduct research on understanding the evolution and maintenance of distinct epigenomic subtypes of small cell lung cancer (SCLC), a highly aggressive lung cancer subtype. The project aims to elucidate the mechanistic roles of lineage factors, particularly NKX2-1, in the development and adaptation of...
- The U.S. National Cancer Institute (NCI) has awarded a $3,480,276 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute. The funding will support a 4-year research initiative to systematically uncover the genomic heterogeneity of pediatric and adolescent/young adult Philadelphia chromosome-positive (Ph+) and ABL-class Ph-like acute lymphoblastic leukemia (ALL). The overarching goals are to...
- The University of Chicago was awarded a $230,010 Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to conduct research on uncovering the cellular and molecular drivers behind the aggressive metastatic potential of small cell lung cancer (SCLC). The project aims to leverage innovative human pluripotent stem cell-derived models of SCLC to gain deeper insights into this complex issue. By examining cell behavior in both primary tumors and...
- This $459,000 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research conducted by the New York Institute of Technology (NYIT) to gain crucial insights into the biology of choroid plexus tumors, with the goal of developing novel therapeutic strategies. The research aims to utilize accurate experimental models to better understand the differentiation and tumorigenesis of the choroid plexus, a critical structure within the brain....
- This $521,579 Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports research to identify critical regulators controlling clear cell renal cell carcinoma (CCRCC) lung metastasis. The University of Texas Southwestern Medical Center, the awardee, will conduct a genome-wide CRISPR screen to characterize the role of the hepatic leukemia factor (HLF) in CCRCC lung metastasis and examine the underlying molecular...